Latest Content

At IDWeek, the company reported promising phase 1/2 trial results for its shingles vaccine candidate Z-1018, demonstrating strong immune responses and favorable tolerability.

Cornelius Clancy, MD, discusses insights from the real-world clinical analysis of the US cohort of the PROVE study.

Lori Handy, MD, MSCE, emphasized that rebuilding public trust requires continuous engagement and a collective rethinking of medical communication.

Phase 3 results for tebipenem HBr suggest an oral carbapenem could provide an effective alternative to IV therapy for multidrug-resistant UTIs.

A systematic review presented at IDWeek 2025 found that pneumococcal serotypes unique to Merck’s 21-valent conjugate vaccine, Capvaxive, are more prevalent among US adults and show higher rates of antibiotic resistance compared to those unique to PCV20.

At IDWeek 2025, Lori Handy, MD, MSCE, discussed how clinicians can strengthen vaccine communication by engaging openly and partnering with trusted community messengers.

Researchers say affordable lenacapavir could transform global HIV prevention efforts amid rising infection rates.

Invivyd’s Chief Scientific Officer Robert Allen, PhD, provides insights on the company's investigational monoclonal antibody, VYD2311, as well as its REVOLUTION clinical program.

George Sakoulas, MD, discusses how updated guidelines recommend shorter antibiotic courses (5 to 7 days) for patients with pneumonia, emphasizing that early aggressive treatment within the first 72 hours is crucial for reducing hospital stays and improving patient outcomes.

Nicholas P. Marshall, MD, FAAP, discussed how generative AI can help streamline infectious disease workflows and enhance evidence-based care at IDWeek 2025 in Atlanta.

IDWeek Chair, Infectious Diseases Society of America, Yohei Doi, MD, provides some insights on the happenings at this year’s event.

Combined or individual use of maternal RSVpreF and infant nirsevimab achieved high antibody levels without safety concerns, supporting current RSV prevention strategies.

A nationwide analysis found that more than 1,500 additional HIV specialists are needed—particularly in the south—to meet national HIV care targets, underscoring major geographic and socioeconomic disparities in provider access.